Vincent P C, Young G A, Buck M, Benson W J
Aust N Z J Med. 1985 Feb;15(1):10-5. doi: 10.1111/j.1445-5994.1985.tb02722.x.
Low dose cytarabine (10 mg m-2, 12 hourly by subcutaneous injection) was used to treat four patients with acute non-lymphoblastic leukemia, two of whom had failed standard induction chemotherapy, and two patients with refractory anemia with excess blasts in transformation. Following treatment two patients entered complete remission (CR) and two patients had survivals of ten and 18 months in stable partial remission. All patients have died, four of progressive or recurrent leukemia, one of a treatment-related intracerebral hemorrhage, and one of lung carcinoma while in CR. Our experience, and a review of the literature, suggest that in general low dose cytarabine is well tolerated, although myelosuppression is common and thrombocytopenia can be a major problem. This form of treatment appears to offer a useful alternative to intensive induction chemotherapy in those patients in whom such treatment is usually poorly tolerated, and has the advantage of being able to be given to an outpatient.
低剂量阿糖胞苷（10 mg/m²，皮下注射，每12小时一次）用于治疗4例急性非淋巴细胞白血病患者，其中2例对标准诱导化疗无效，2例为难治性贫血伴原始细胞增多转化型。治疗后，2例患者进入完全缓解（CR），2例患者分别存活10个月和18个月，处于稳定的部分缓解状态。所有患者均已死亡，4例死于白血病进展或复发，1例死于与治疗相关的脑出血，1例在CR期死于肺癌。我们的经验以及文献回顾表明，一般来说低剂量阿糖胞苷耐受性良好，尽管骨髓抑制很常见，血小板减少可能是一个主要问题。对于那些通常对强化诱导化疗耐受性较差的患者，这种治疗方式似乎是一种有用的替代方法，并且具有能够门诊给药的优势。
